Exploring perceptions of and decision-making about CFTR modulators.

Autor: Landess L; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Prieur MG; Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Brown AR; Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Dellon EP; University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Jazyk: angličtina
Zdroj: Pediatric pulmonology [Pediatr Pulmonol] 2024 Jun; Vol. 59 (6), pp. 1614-1621. Date of Electronic Publication: 2024 Mar 08.
DOI: 10.1002/ppul.26953
Abstrakt: Introduction: Cystic fibrosis (CF) treatment has increasingly focused on highly effective modulators. Despite measurable benefits of modulators, there is little guidance for CF care team members on providing education and support to patients regarding initiation of these therapies. We aimed to explore patient, caregiver, and clinician perceptions of modulators and influences on decisions about starting cystic fibrosis transmembrane regulator (CFTR) modulators.
Methods: We conducted semistructured interviews with CF clinicians, adults with CF, and caregivers of children with CF. We reviewed audio recordings and coded responses to identify central themes.
Results: We interviewed 8 CF clinicians, 9 adults with CF, and 11 caregivers of children with CF. Themes centered on emotional responses to modulator availability, influences on decision-making, concerns about side effects, impact of modulators on planning for the future, the benefits of the multidisciplinary CF care team in supporting treatment decisions, and the unique needs of people with CF who are not eligible for modulators. Clinicians described changes in conversations about modulators since the approval of elexacaftor/tezacaftor/ivacaftor, specifically greater willingness to prescribe with less nuanced conversations with patients and/or caregivers regarding their use.
Conclusion: Based on perspectives and experiences of CF clinicians, adults with CF, and caregivers of children with CF, we suggest clinicians approach conversations about CFTR modulators thoughtfully and thoroughly, utilizing the multidisciplinary model of CF care in exploring patient and caregiver emotions while filling in knowledge gaps, asking about treatment goals beyond potential clinical benefit, and having compassionate conversations with those who are ineligible for modulators.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: